Equity Overview
Price & Market Data
Price: $1.47
Daily Change: -$0.005 / 0.34%
Range: $1.45 - $1.51
Market Cap: $158,918,768
Volume: 42,629
Performance Metrics
1 Week: 14.06%
1 Month: -10.98%
3 Months: -52.13%
6 Months: -79.58%
1 Year: -80.03%
YTD: -52.75%
Company Details
Employees: 155
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to reverse the immune evasion effect of serine-threonine kinase 11 loss-of-function mutations for treating lung cancer. The company was founded in 2017 and is headquartered in Boston, Massachusetts.